Reported
Lowest–highest estimate
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Samsung Biologics Co Ltd
KRX:207940
Samsung Biologics Co Ltd
KRX:207940
Price:
1 411 000
KRW
-2.62%
Market Closed
Market Cap:
₩68.5T
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently viewed
Price
Wall St Price Targets
Price Forecast
Based on 30 analysts
Based on 30 analysts
+37% Upside
from
₩1 411 000
today
Samsung Biologics Co Ltd (207940)’s 12-month stock price forecast through November 2027 has a consensus target of ₩1 938 000, implying 37% upside. The forecast is based on price targets from 30 Wall Street analysts.
Analyst Rating
No ratings yet
No ratings yet
Samsung Biologics Co Ltd Competitors:
Price Targets
Price Targets
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is Samsung Biologics Co Ltd's stock price target?
Price Target
1 938 000
KRW
1 938 000
KRW
According to Wall Street analysts, the average 1-year price target for Samsung Biologics Co Ltd is 1 938 000 KRW with a low forecast of 1 363 500 KRW and a high forecast of 2 292 217.62 KRW.
What is the Revenue forecast for Samsung Biologics Co Ltd?
Projected CAGR
14%
14%
Over the last 11 years, the compound annual growth rate for Revenue has been 41%. The projected CAGR for the next 7 years is 14%.
What is the Gross Profit forecast for Samsung Biologics Co Ltd?
Projected CAGR
15%
15%
The compound annual growth rate for Gross Profit over the next 3 years is 15%.
What is the Operating Income forecast for Samsung Biologics Co Ltd?
Projected CAGR
14%
14%
The compound annual growth rate for Operating Income over the next 7 years is 14%.
What is the Pre-Tax Income forecast for Samsung Biologics Co Ltd?
Projected CAGR
16%
16%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 16%.
What is the Net Income forecast for Samsung Biologics Co Ltd?
Projected CAGR
12%
12%
The compound annual growth rate for Net Income over the next 3 years is 12%.
